<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Solifenacin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Solifenacin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Solifenacin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11529" href="/d/html/11529.html" rel="external">see "Solifenacin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="128520" href="/d/html/128520.html" rel="external">see "Solifenacin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F221517"><span class="drugH1">Brand Names: US</span>
<ul>
<li>VESIcare;</li>
<li>VESIcare LS</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868250"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Solifenacin Succinate;</li>
<li>APO-Solifenacin [DSC];</li>
<li>Auro-Solifenacin;</li>
<li>BIO-Solifenacin;</li>
<li>JAMP-Solifenacin;</li>
<li>M-Solifenacin Succinate;</li>
<li>MED-Solifenacin;</li>
<li>PMS-Solifenacin;</li>
<li>PRZ-Solifenacin;</li>
<li>SANDOZ Solifenacin;</li>
<li>TARO-Solifenacin;</li>
<li>TEVA-Solifenacin;</li>
<li>VESIcare</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F221536"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F221520"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e512851c-5f54-40d3-beee-88b90862f34c">Overactive bladder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder: Oral:</b> Initial: 5 mg once daily; if tolerated, may increase to 10 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses: </i>
<b>Oral suspension:</b> Administer as soon as possible as long as ≤12 hours have passed. If &gt;12 hours have passed, skip dose and administer next dose at usual time.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991437"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;30 mL/minute: Maximum dose: 5 mg/day</p></div>
<div class="block doha drugH1Div" id="F50988731"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Maximum dose: 5 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is not recommended.</p></div>
<div class="block dot drugH1Div" id="F57445911"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema and hypersensitivity reactions (eg, anaphylaxis):</b> Discontinue therapy immediately with anaphylaxis or angioedema involving the tongue, hypopharynx, or larynx; initiate supportive care.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS effects:</b> Consider decreasing dose or discontinuing therapy if CNS effects occur (eg, headache, confusion, hallucination, somnolence, dementia).</p></div>
<div class="block dop drugH1Div" id="F54492440"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="128520" href="/d/html/128520.html" rel="external">see "Solifenacin: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cfba3c5-bb68-46a2-9ab8-73ec41e1d445">Neurogenic detrusor overactivity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurogenic detrusor overactivity</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32007426','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32007426','lexi-content-ref-manu.1'])">Ref</a></span>): Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension (1 mg/mL):</p>
<p style="text-indent:-2em;margin-left:6em;">9 to 15 kg: Oral: Initial dose: 2 mg once daily; may titrate every 3 weeks to lowest effective dose. Maximum daily dose: 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;15 to 30 kg: Oral: Initial dose: 3 mg once daily; may titrate every 3 weeks to lowest effective dose. Maximum daily dose: 5 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;30 to 45 kg: Oral: Initial dose: 3 mg once daily; may titrate every 3 weeks to lowest effective dose. Maximum daily dose: 6 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;45 to 60 kg: Initial dose: Oral: 4 mg once daily; may titrate every 3 weeks to lowest effective dose. Maximum daily dose: 8 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;60 kg: Initial dose: Oral: 5 mg once daily; may titrate every 3 weeks to lowest effective dose. Maximum daily dose: 10 mg<b>/day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b>
<i></i>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F54492441"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">9 to 15 kg: Maximum daily dose: 2 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;15 to 45 kg: Maximum daily dose: 3 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;45 to 60 kg: Maximum daily dose: 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;60 kg: Maximum daily dose: 5 mg/<b>day</b>.</p></div>
<div class="block dohp drugH1Div" id="F54492442"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: There are no dosage adjustments provided in manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment:</p>
<p style="text-indent:-2em;margin-left:6em;">9 to 15 kg: Maximum daily dose: 2 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;15 to 45 kg: Maximum daily dose: 3 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;45 to 60 kg: Maximum daily dose: 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;60 kg: Maximum daily dose: 5 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended.</p></div>
<div class="block arsc drugH1Div" id="F58706074"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic agents, including solifenacin, may cause reversible, dose-dependent anticholinergic effects, including, but not limited to CNS effects (eg, <b>confusion</b>, <b>dizziness,</b>
<b>drowsiness</b>, <b>hallucinations</b>), GI effects (eg, <b>constipation, xerostomia</b>), ophthalmic effects (eg, <b>blurred vision</b>), cardiovascular effects (eg, prolonged QT interval on ECG) in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22070184','lexi-content-ref-35708534','lexi-content-ref-34742663','lexi-content-ref-20596778','lexi-content-ref-21830836','lexi-content-ref-36336627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22070184','lexi-content-ref-35708534','lexi-content-ref-34742663','lexi-content-ref-20596778','lexi-content-ref-21830836','lexi-content-ref-36336627'])">Ref</a></span>). Heat prostration due to decreased sweating can also occur in a hot environment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney or hepatic impairment</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of multiple concurrent medications with anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18332297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18332297'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting or undiagnosed dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19636034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19636034'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting decreased GI motility or GI obstructive disorders</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting narrow-angle closure glaucoma</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F221488"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Constipation (children, adolescents, and adults: 5% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Constipation table link" class="lexi-table-link" data-table-id="lexi-content-constipation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-constipation')">table 1</a>)</span><span class="table-link" style="display:none;">Constipation</span>, xerostomia (children and adolescents: 3%; adults: 11% to 28%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia')">table 2</a>)</span><span class="table-link" style="display:none;">Xerostomia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Constipation" frame="border" id="lexi-content-constipation" rules="all">
<caption style="text-align:center;">
<b>Solifenacin: Adverse Reaction: Constipation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Solifenacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Solifenacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neurogenic detrusor overactivity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">95</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,216</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">578</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,216</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia" frame="border" id="lexi-content-xerostomia" rules="all">
<caption style="text-align:center;">
<b>Solifenacin: Adverse Reaction: Xerostomia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Solifenacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Solifenacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral suspension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Neurogenic detrusor overactivity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">95</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,216</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">578</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,216</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (1%), lower extremity edema (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents: 1%), dyspepsia (4%), nausea (3%), upper abdominal pain (2%), vomiting (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention (1%), urinary tract infection (children, adolescents, and adults: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (1%), drowsiness (children and adolescents: 1%), fatigue (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (4% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Blurred Vision table link" class="lexi-table-link" data-table-id="lexi-content-blurred-vision" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-blurred-vision')">table 3</a>)</span><span class="table-link" style="display:none;">Blurred Vision</span>, dry eye syndrome (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Blurred Vision" frame="border" id="lexi-content-blurred-vision" rules="all">
<caption style="text-align:center;">
<b>Solifenacin: Adverse Reaction: Blurred Vision</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Solifenacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Solifenacin)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,216</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Oral tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">578</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,216</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Gastrointestinal: Fecal impaction, gastrointestinal obstruction, intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema, prolonged QT interval on ECG (Bray 2017), tachyarrhythmia (including atrial fibrillation, increased heart rate, palpitations, and tachycardia) (Gratzke 2018), torsades de pointes (Bray 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, exfoliative dermatitis, urticaria (Younas 2022), xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite, dysgeusia, gastroesophageal reflux disease, sialadenitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, hepatic disease, increased gamma-glutamyl transferase, increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema (Younas 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Behavioral changes (Raman 2023), confusion, delirium, dizziness (Raman 2023), hallucination, headache (Gratzke 2018), myasthenia, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Glaucoma</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry nose</p></div>
<div class="block coi drugH1Div" id="F221502"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, angioedema) to solifenacin or any component of the formulation; urinary retention (tablet only); gastric retention; uncontrolled narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindication (not in the US labeling): Dialysis</p></div>
<div class="block war drugH1Div" id="F221486"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Potentially life-threatening angioedema involving the face, lips, tongue, and/or larynx have been reported; some cases have occurred after the first dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Anaphylactic reactions have been reported rarely; may be life-threatening.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alzheimer disease: Preliminary data suggest that long-term use of anticholinergics may potentially adversely affect the clinical course of Alzheimer disease in patients receiving cholinesterase inhibitors (Lu 2003; Sink 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma; use is contraindicated in uncontrolled narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate hepatic impairment (Child-Pugh class B); dosage adjustment required; use is not recommended in patients with severe hepatic impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: Use with caution in patients with a known history of QT prolongation or other risk factors for QT prolongation (eg, concomitant use of medications known to prolong QT interval, electrolyte abnormalities). The risk for QT prolongation is dose-related.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required for severe renal impairment (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F221496"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral, as succinate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">VESIcare LS: 5 mg/5 mL (150 mL) [contains methylparaben, propylene glycol, propylparaben; orange flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as succinate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">VESIcare: 5 mg, 10 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block geq drugH1Div" id="F221484"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F221503"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (VESIcare LS Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $2.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Solifenacin Succinate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.57 - $14.65</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.57 - $14.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (VESIcare Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $15.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $15.42</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868251"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as succinate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">VESIcare: 5 mg, 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F221499"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral suspension:</b> Shake well before use. Administer liquid (water or milk) after administration; simultaneous administration of food or liquid may result in bitter taste. Administer with an accurate measuring device, such as an oral syringe.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablet:</b> Administer tablet with water without regard to food. Swallow whole. Do not crush or chew.</p></div>
<div class="block admp drugH1Div" id="F54492443"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral suspension: Shake well before use. Administer liquid (water or milk) after administration; simultaneous administration of food or liquid may result in bitter taste. Administer with an accurate measuring device, such as an oral syringe.</p>
<p style="text-indent:-2em;margin-left:2em;">Missed dose: Administer as soon as possible as long as ≤12 hours have passed. If &gt;12 hours have passed, skip dose and administer next dose at usual time.</p></div>
<div class="block use drugH1Div" id="F221498"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurogenic detrusor overactivity (oral suspension):</b> Treatment of neurogenic detrusor overactivity in pediatric patients ≥2 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder (tablet):</b> Treatment of overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence in adults.</p></div>
<div class="block mst drugH1Div" id="F3878592"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">VESIcare may be confused with Vesanoid, Vessel Care (nutritional supplement)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Solifenacin is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F221530"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F221490"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Solifenacin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Solifenacin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Solifenacin. Management: Limit adult solifenacin doses to 5 mg daily and limit doses in pediatric patients to the recommended weight-based starting dose (and do not increase the dose) when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Solifenacin. Management: Limit adult solifenacin doses to 5 mg daily and limit pediatric doses to the starting dose. Do not use with itraconazole, or for 2 weeks after itraconazole discontinuation, in patients with moderate to severe hepatic impairment or severe renal impairment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: May enhance the adverse/toxic effect of Solifenacin. Specifically, the risk of acute urinary retention may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F221514"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Grapefruit juice may increase the serum level effects of solifenacin. Management: Monitor closely with concurrent use.</p></div>
<div class="block pri drugH1Div" id="F221504"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F16571281"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if solifenacin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F221494"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mini Mental State exam (MMSE) (periodically) (Dantas 2022); creatinine clearance; hepatic function; postvoid residual urine volume (at baseline and as clinically indicated thereafter) (AUA [Lerner 2021]); anticholinergic effects (eg, mental alertness, dizziness, constipation, blurred vision).</p></div>
<div class="block pha drugH1Div" id="F221485"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits muscarinic receptors resulting in decreased urinary bladder contraction, increased residual urine volume, and decreased detrusor muscle pressure.</p></div>
<div class="block phk drugH1Div" id="F221501"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years to Adolescents ≤17 years: Median: 211 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Mean: 600 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~98%, primarily to alpha<sub>1</sub>-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic; via N-oxidation and 4 R-hydroxylation, forms 1 active and 3 inactive metabolites; primary pathway for elimination is via CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents ≤17 years: Oral suspension: Median: 26 hours; prolonged in severe kidney impairment (CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>) or moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 45 to 68 hours following chronic dosing; prolonged in severe renal (CrCl &lt;30 mL/minute) or moderate hepatic (Child-Pugh class B) impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years and Adolescents ≤17 years: Oral suspension: 2 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Tablets: 3 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (69%; &lt;15% as unchanged drug); feces (23%).</p></div>
<div class="block phksp drugH1Div" id="F51221455"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: There is a 2.1-fold increase in AUC and 1.6-fold increase in half-life of solifenacin in patients with severe impairment (CrCl &lt;30 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: There is a 2-fold increase in the half-life and 35% increase in AUC of solifenacin in patients with moderate impairment (Child-Pugh class B).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: In elderly patients (65 to 80 years), C<sub>max</sub>, AUC, and half-life values were 20% to 25% higher.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539929"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Kinzy | Sanadcare | Urilax | Urinacin | Vesicare | Vesitone</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cistil | Novurit | Pisono | Solfacina | Solifen | Solifenacina teva</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Belmacina | Solifenacin 1a pharma | Solifenacin accord | Solifenacin Aristo | Solifenacin genericon | Solifenacin hcs | Solifenacin stada | Solifenacinsuccinat mylan | Vesicare | Vesisol</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Solicare | Solifenacin dr. reddy's | Solifenacin lupin | Solifenacin mylan | SOLIFENACIN SANDOZ | Vesicare</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Solicare | Solider | Solifen | Solurin | Utrobin | Vesinac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pelvicare | Solifenacin krka | SOLIFENACIN SANDOZ | Solifenacine | Solifenacine ab | Solifenacine eg | Solifenacine mylan | Vesicare</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Asolfena | Lanivasin | Solifenacin | Solifenacin accord | Solifenacin medica | Solifenacon | Solifenax | Truzor | Vesicare | Vesifix | Vesimed | Vesisol | Zevesin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Impere | Samile | Succinato de solifenacina | Vesicare</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin mepha | Solifenacin nobel | SOLIFENACIN SANDOZ | Solifenacin spirig HC | Solifenacin zentiva | Vesicare</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Vesicare</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Vesicare</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Blacidec | Solifen | Trabis | Vesicare</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Arusol | Asolfena | Folinar | Muscarisan | Sentacurin | Solicare | Solifenacin accord | Solifenacin actavis | Solifenacin apotex | Solifenacin aurovitas | Solifenacin farmax | Solifenacin g.l. pharma | Solifenacin medreg | Solifenacin msn | Solifenacin mylan | Solifenacin pmcs | Solifenacin Teva pharma | Solifenacin vipharm | Soliflow | Solixa | Vesicare | Zabcare | Zevesin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin 1a pharma | Solifenacin aaa pharma | Solifenacin abz | Solifenacin accord | Solifenacin axunio | Solifenacin glenmark | Solifenacin heumann | Solifenacin micro labs | Solifenacin ratiopharm | Solifenacin succinat zentiva | Solifenacin uropharm | Solifenacinsuccinat aurobindo | Solifenacinsuccinat mylan | Solifenacinsuccinat tillomed | Vesicare | Vesikur</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Facid 5 | Solifen | Vejicalm</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Calm | Continental | Novurit</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin pmcs | Tamisten | Vesicare</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Slowurge | Sofenacin | Solitract | Urginafect | Vesicare</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Belmacina | Dicrisol | Sincal | Solifenacin zentiva | Solifenacina alter | Solifenacina aristo | Solifenacina aurovitas | Solifenacina cinfa | Solifenacina combix | Solifenacina krka | Solifenacina mylan | Solifenacina Normon | Solifenacina pensa | Solifenacina Qualigen | Solifenacina ratiopharm | Solifenacina sandoz | Solifenacina stada | Solifenacina sun | Solifenacina tarbis | Solifenacina tecnigen | Solifenacina teva | Solifenacina vir | Tamisten | Vesicare | Vesurol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin | Solifenacin accord | Solifenacin krka | Solifenacin mylan | Solifenacin orion | SOLIFENACIN SANDOZ | Solifenacin stada | Vesicare</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Solifenacine accord | Solifenacine arrow | Solifenacine besin | Solifenacine biogaran | Solifenacine cristers | Solifenacine eg | Solifenacine evolugen | Solifenacine hcs | Solifenacine mylan | Solifenacine sandoz | Solifenacine teva | Solifenacine zenti | Solifenacine zydus | Vesicare</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin | Solifenacin medreich | Solifenacin succinate sandoz | Vesicare</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cecure | Nacerfin | Sivenacin | Solicare | Solicin | SOLIFENACIN SANDOZ | Solnatec</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Sofcare | Vesicare</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Soline | SoliPhar | Solven | Urotrim | Vesicare</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Asolfena | Belsanor | Vesicare</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin apotex | Solifenacin clonmel | Solifenacin succinate rowex | Solifenacin teva | Vesitirim</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin trima | Vesicare</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Antab | Bispec | Regusol | Restream | Samlifen | Solbeg | Soliact | Solicept | Solidif | Solikem | Solina | Solipress | Soliten | Vesiact | Vesifa | Vesilife</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Incoves | Olidax | Solifenacina Aurobindo | Solifenacina doc | Solifenacina krka | Solifenacina mylan | Solifenacina sandoz | Solifenacina teva | Titenur | Vesacin | Vesiker</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Kinzy | Sanadcare | Sulfi | Urifix | Urilax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Vesicare</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bispec | Blacidec | Solifen | Solikem | Urysoren | Vesicare</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">A-care | Aircare | Besigen | Besigum | Besimine | Boryung solifenacin | Carecsil | Caresil | Celfelina | CMcare | Ct care | Curenacin | Hufenacin | Hyundai solifenacin succinate | Ilyangbio solifenacin succinate | Infenacin | J care | Medifenacin | Newfecin | Nexfenacin | Oab | Oabi | Rp soli | Samsung solifenacin | Solacin | Solbecin | Solbena | Solcil | Solcin | Solenacin | Solfecin | Solfelac | Solfelicin | Solfenacin | Solfipen | Solibe | Solica | Solicare | Solicin | Solicitol | Solicon | Solif | Solifare | Solife | Solifecin | Solifena | Solifenocil | Solinacin | Solipair | Solipro | Solistop | Solitear | Solive | Solnacin | Solpro | Soltonicin | Soul q | Teva solifequal | Unifenacin | Urifena | Urocare | Urofenacin | Urotera | Utocare | Vescan | Vesi q | Vesicalin | Vesicam | Vesicare | Vesicover | Vesicy | Vesifena | Vesigeum | Vesikol | Vesina | Vesisi | Vesisol | Vesistar | Welluro | Yosicare | Yunacare</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Urilax | Vasicare</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Solifenacine arrow | Urisol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Asolfena | Solifenacin accord | Solifenacin pmcs | Sozabel | Tamisten | Vesicare | Zevesin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Pelvicare | Solifenacin ratiopharm | Solifenacine eg | Vesicare</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Asolfena | Solifenacin accord | Solifenacin pmcs | Tamisten | Vesicare | Zevesin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Solficar | Veca</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Osolfenacare</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Continental | Vesicare</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Renaxin | Sofcare | Vesicare</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Solifen | Vesizen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Solifenacinesuccinaat Accord | Solifenacinesuccinaat Aurobindo | Solifenacinesuccinaat CF | Solifenacinesuccinaat fisher | Solifenacinesuccinaat Mylan | Solifenacinesuccinaat Sandoz | Solifenacinesuccinaat SUN | Solifenacinesuccinaat teva | Vesicare</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin accord | Solifenacin krka | Solifenacin mylan | SOLIFENACIN SANDOZ | Vesicare | Vesikur</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin mylan | Solifenacin viatris</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Blacidec | Fenacina | Solicin | Solivitae | Solixil | Utocare | Vesicare</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Vesicare | Vesifix</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Afenix | Fenacidan | Fenaso | Medonate | Prosle | Regaflo | Solcina | Solfy | Solicept | Solif | Solifen | Solinate | Soliscot | Soloflo | Ufi | Urgesin | Uricontrol | Vesibar | Vesicare | Vesitrim | Vezitic | Visera</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adablok | Afenix | Asolfena | Beloflow | Silamil | Solifenacin mylan | Solifenacin stada | Solifurin | Soreca | Symcare | Uronorm | Vesicare | Vesisol | Vesoligo | Zevesin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Vesicare | Vesicare ls</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Blaxi | Flomin | Solifenacin | Solifenacin Aristo | Solifenacina generis | Uriclin | Vesicare</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Novurit | Solifen</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Kinzy | Sanadcare | Solfesire | Soliget | Sulfi | Vesicare</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Asolfena | Solifenacin actavis | Solifenacin aurobindo | Vesicare | Vesistad | Vezimed | Zevesin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Soliksa xantis | Vesicare | Vesigamp</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Fensolin | Kinzy | Lifance | Solfisan | Urilax | Vesicare</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Solifenacin | Solifenacin accord | Solifenacin krka | Solifenacin medical valley | Solifenacin orion | SOLIFENACIN SANDOZ | Solifenacin stada | Solifenacin teva | Vesicare | Vesikur</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Vesicare</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Asolfena | Solifenacin lek | Sulfesa | Urotecin | Vesicare | Zabcare</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Arusol | Asolfena | Folinar | Karesol | Renemed | Sentacurin | Solifenacin actavis | Solifenacin farmax | Solifenacin glenmark | Solifenacin krka | Solifenacin medreg | Solifenacin mylan | Solifenacin pharmevid | Solifenacin pmcs | SOLIFENACIN SANDOZ | Solifenacin stada | Solifenacin teva | Soliflow | Solimed | Solixa | Urokur | Zabcare | Zevesin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Sofcare | Vesicare</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Vesicare</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bevlasin | Kinzy | Kontifen | Natysin | Solfesire | Solifas | Soliron | Solysin | Vesicare | Vesifix | Zevesin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bladerin | Dalisoon | Naliso | Sofena | Soflow | Solifenacin | Solin | Solinacin | Vebacin | Vesicare</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Nigisem | Solecyst | Solicin | Solifenacin xantis | Vesicare</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Vesizen</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Sifel | Solnef | Sygen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Solestan | Solifenacin | Solirest | Solvicyd | Utroves | Vesicare | Vesifin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Vesizen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28845232">
<a name="28845232"></a>Bray JJH, Hancox JC. Solifenacin linked QT interval prolongation and torsades de pointes. <i>Ther Adv Drug Saf</i>. 2017;8(7):245-247. doi:10.1177/2042098617702616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/28845232/pubmed" id="28845232" target="_blank">28845232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19636034">
<a name="19636034"></a>Carrière I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. <i>Arch Intern Med</i>. 2009;169(14):1317-1324. doi:10.1001/archinternmed.2009.229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/19636034/pubmed" id="19636034" target="_blank">19636034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22070184">
<a name="22070184"></a>Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. <i>CNS Neurosci Ther</i>. 2012;18(2):167-174. doi:10.1111/j.1755-5949.2011.00248.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/22070184/pubmed" id="22070184" target="_blank">22070184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35320336">
<a name="35320336"></a>Dantas LP, Forte ARCC, Lima BC, et al. Treatment of bladder dysfunction with solifenacin: is there a risk of dementia or cognitive impairment?<i> Braz J Med Biol Res.</i> 2022;55:e11721. doi:10.1590/1414-431X2021e11721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/35320336/pubmed" id="35320336" target="_blank">35320336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35708534">
<a name="35708534"></a>de Nunzio C, Nacchia A, Gravina C, et al. Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database. <i>Minerva Urol Nephrol</i>. 2022;74(6):761-779. doi:10.23736/S2724-6051.22.04849-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/35708534/pubmed" id="35708534" target="_blank">35708534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31757230">
<a name="31757230"></a>Dykewicz MS, Lam JK. Drug hypersensitivity reactions. <i>Med Clin North Am</i>. 2020;104(1):109-128. doi:10.1016/j.mcna.2019.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/31757230/pubmed" id="31757230" target="_blank">31757230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32007426">
<a name="32007426"></a>Franco I, Hoebeke P, Baka-Ostrowska M, et al. Long-term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open-label studies. <i>J Pediatr Urol</i>. 2020;16(2):180.e1-180.e8. doi:10.1016/j.jpurol.2019.12.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/32007426/pubmed" id="32007426" target="_blank">32007426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29866467">
<a name="29866467"></a>Gratzke C, van Maanen R, Chapple C, et al. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: A randomised, multicentre phase 3 study (SYNERGY II). <i>Eur Urol</i>. 2018;74(4):501-509. doi:10.1016/j.eururo.2018.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/29866467/pubmed" id="29866467" target="_blank">29866467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol</i>. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12837675">
<a name="12837675"></a>Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. <i>Am J Geriatr Psychiatry.</i> 2003;11:458-461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/12837675/pubmed" id="12837675" target="_blank">12837675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17062299">
<a name="17062299"></a>Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R. Solifenacin succinate for the treatment of symptoms of overactive bladder. <i>Clin Ther</i>. 2006;28(9):1247-1272. doi:10.1016/j.clinthera.2006.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/17062299/pubmed" id="17062299" target="_blank">17062299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34742663">
<a name="34742663"></a>Matta R, Gomes T, Juurlink D, Jarvi K, Herschorn S, Nam RK. Receipt of overactive bladder drugs and incident dementia: A population-based case-control study. <i>Eur Urol Focus</i>. 2022;8(5):1433-1440. doi:10.1016/j.euf.2021.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/34742663/pubmed" id="34742663" target="_blank">34742663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20596778">
<a name="20596778"></a>Meek PD, Evang SD, Tadrous M, Roux-Lirange D, Triller DM, Gumustop B. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. <i>Dig Dis Sci</i>. 2011;56(1):7-18. doi:10.1007/s10620-010-1313-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/20596778/pubmed" id="20596778" target="_blank">20596778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21830836">
<a name="21830836"></a>Oefelein MG. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. <i>Drug Saf</i>. 2011;34(9):733-754. doi:10.2165/11592790-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/21830836/pubmed" id="21830836" target="_blank">21830836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36336627">
<a name="36336627"></a>Raman G, Tunnicliffe D, Lai E, Bennett T, Caldwell P. Safety and tolerability of solifenacin in children and adolescents with overactive bladder- a systematic review. <i>J Pediatr Urol</i>. 2023;19(1):19.e1-19.e13. doi:10.1016/j.jpurol.2022.09.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/36336627/pubmed" id="36336627" target="_blank">36336627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18332297">
<a name="18332297"></a>Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. <i>Arch Intern Med</i>. 2008;168(5):508-513. doi:10.1001/archinternmed.2007.106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/18332297/pubmed" id="18332297" target="_blank">18332297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22624162">
<a name="22624162"></a>Shamliyan T, Wyman J, Kane RL. <i>Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness</i>. Rockville (MD): Agency for Healthcare Research and Quality (US); April 2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/22624162/pubmed" id="22624162" target="_blank">22624162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18384584">
<a name="18384584"></a>Sink KM, Thomas J 3rd, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: Long-term functional and cognitive outcomes. <i>J Am Geriatr Soc.</i> 2008;56(5):847-853.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/18384584/pubmed" id="18384584" target="_blank">18384584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vesicare.1">
<a name="Vesicare.1"></a>Vesicare (solifenacin) [summary of product characteristics]. Surrey, United Kingdom: Astellas Pharma Ltd; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vesicare.2">
<a name="Vesicare.2"></a>Vesicare (solifenacin succinate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vesicare.3">
<a name="Vesicare.3"></a>Vesicare (solifenacin succinate) [product monograph]. Markham, Ontario, Canada: Astellas Pharma Canada, Inc; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VESIcare.4">
<a name="VESIcare.4"></a>VESIcare LS (solifenacin succinate) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33452148">
<a name="33452148"></a>Younas U, Shafiq O, Mansoor SN, Khalil MT. Solifenacin-induced acute urticaria and angioedema: a rare adverse effect. <i>Postgrad Med J</i>. 2022;98(1160):420-421. doi:10.1136/postgradmedj-2020-138375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/33452148/pubmed" id="33452148" target="_blank">33452148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solifenacin-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10313 Version 421.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
